Advertisement

Corrigendum to ‘Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)’ [European Journal of Cancer 169 (2022) 1–9]

Published:November 16, 2022DOI:https://doi.org/10.1016/j.ejca.2022.10.001
      The authors regret there were mistakes in two figures for the wrong direction of functional scales. High scores for functional scales represent high or healthy level of functioning, but the original direction is opposite. These mistakes were found in Figure 2A, Figure 2C, Figure 3A, Figure 3C, and their figure legends. The outcome results are not affected.
      Image 1
      Figure 2 Mean change scores for QLQ-C30 and QLQ-G.I.NET21 scales from baseline to the last available visit. (A) Global health status and functioning scales of QLQ-C30 (B) symptom scales of QLQ-C30 (C) functioning scales of QLQ-G.I.NET21 (D) symptom scales of QLQ-G.I.NET21.
      Image 2
      Figure 3 Mean change scores for QLQ-C30 and QLQ-G.I.NET21 scales from baseline to the week 16. (A) Global health status and functioning scales of QLQ-C30 (B) symptom scales of QLQ-C30 (C) functioning scales of QLQ-G.I.NET21 (D) symptom scales of QLQ-G.I.NET21.
      The authors would like to apologize for any inconvenience caused.

      Linked Article